Predictmedix Inc.
PMED:CSE / PMEDF:OTCQB

NEWS RELEASE

PREDICTMEDIX IS PARTNERING WITH MCGILL RESEARCHERS FOR CLINICAL RESEARCH

Toronto, ON / November 10, 2020/ Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) ("Predictmedix" or the "Company") is pleased to announce that the company is partnering with the research group led by Dr. Samira Rahimi for clinical research. Professor Rahimi is an Assistant Professor in McGill University's Department of Family Medicine, associate member of McGill's Electrical and Computer Engineering Department, and affiliated scientist at the Lady Davis Institute for Medical Research of Jewish General Hospital.

Predictmedix will be working with Dr. Rahimi's research group for its three industry verticals which include screening for infectious disease associated symptoms, screening for cannabis/alcohol impairment along with mental health screening technologies which are being developed by the company.

"We are extremely excited with the partnership with Dr. Samira Rahimi's team. Dr. Rahimi is one of the most recognized AI – healthcare scientists in Canada and we look forward to with her and her research team for our 3 major verticals.", said Dr. Rahul Kushwah, COO of Predictmedix Inc.

Speaking of the partnership, Dr. Rahimi commented, "My team and I are looking forward to working with Predictmedix team. Predictmedix is one of the young and leading AI companies which aims to improve our healthcare system through innovative and cutting-edge digital health technologies."

Biography of Dr. Samira Rahimi:

Samira Rahimi Eng. Ph.D. is an Assistant Professor in the Department of Family Medicine at McGill University, and affiliated scientist at Lady Davis Institute for Medical Research of the Jewish General Hospital. She is FRQS Junior 1 Research Scholar, and regular member of Institute of Electrical and Electronics Engineers (IEEE), Association for the Advancement of Artificial Intelligence (AAAI), OBVIA, CIRRELT-IVADO, Cardiometabolic Health Diabetes and Obesity research network (CMDO), Canadian Consortium on Neurodegeneration in Aging (CCNA) and society officer of Canadian Operational Research Society.

She completed her postdoctoral training at Family and Emergency Medicine Department of Université Laval, and her doctorate studies (in Industrial and System Engineering with a focus on health care systems) at Mechanical Engineering Department of Université Laval. She is the recipient of numerous scholarships, fellowships, and awards among them the 2015 Canada Women in Engineering award of IEEE.

With an interdisciplinary background, she is interested in the development, evaluation, and implementation of clinical decision support tools and patient decision aids, as well as integrating human-centered AI tools in primary health care.

Her work as Principal Investigator has been funded by the Fonds de recherche du Québec – Santé (FRQS), Natural Sciences and Engineering Research Council (NSERC), Roche Canada, Brocher Foundation (Switzerland), and the Strategy for Patient-Oriented Research (SPOR)-Canadian Institutes of Health Research (CIHR).

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence ("AI") company developing disruptive tools for impairment testing and healthcare. It is intended that the Company's cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer's disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease. To find out more visit us at www.predictmedix.com

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time."

For further information, please contact:

Dr. Rahul Kushwah, Chief Operating Officer
Tel: 647 889-6916
Email: rahul@predictmedix.com

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.